A Phase 2 Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
Condition: Overactive Bladder Interventions: Drug: Solabegron modified release tablets, low dose; Drug: Solabegron modified release tablets, high dose; Drug: Matching Placebo Sponsor: Velicept Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bed Wetting | Enuresis | Overactive Bladder | Overactive Bladder Syndrome | Study | Women